Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Comment by Baylor1965on Jul 14, 2011 1:06pm
301 Views
Post# 18831632

RE: RE: RE: news leaking ?

RE: RE: RE: news leaking ?do you really think that management is that stupid????

Really now...why can't it be that the study was presented at the symposium to well established TBI experts and medical professionals  who, incidentally, might understand the meaning of these findings and what these findings might infer to a TBI cure alot more than you and I...is it possible that the presentation might interest a few of these experts into buying SCT shares?

Stop drinking from the glass that is half full.


Baylor
  
Bullboard Posts